# Mythic Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mythic-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.mythictx.com
- Total disclosed funding: $122M
- Latest round: Series B (Nov 19, 2021)
- Investors on record: 11

## About

Mythic Therapeutics, Inc. focuses on developing innovative antibody-drug conjugates (ADCs) that deliver targeted cancer therapies, aiming to improve treatment outcomes for oncology patients while reducing side effects related to conventional chemotherapy.Founded in 2017, Mythic Therapeutics, Inc. is based in Waltham, US, and specializes in the development of advanced cancer therapies. The company has conducted two deals, with the latest being a Series B funding round in November 2021. Brian Fiske is the founder of the company.Mythic Therapeutics specializes in the development of advanced antibody-drug conjugates (ADCs), designed to deliver chemotherapy directly to cancerous cells while minimizing exposure to healthy tissues. Their flagship technology, FateControl™, enhances ADC uptake in malignant cells, increasing therapeutic efficacy and reducing side effects. The primary users of Mythic's products include oncology patients and healthcare providers seeking innovative treatment options. The company targets global markets with high demand for advanced cancer treatments, focusing on regions such as North America, Europe, and parts of Asia.Mythic Therapeutics operates on a business model that involves partnerships with healthcare providers and pharmaceutical companies for the distribution of their ADC products. Revenue generation stems from clinical collaborations, licensing agreements, and direct sales to hospitals and treatment centers, engaging in B2B transactions that provide access to their proprietary FateControl™ technology. Pricing structures for their services and products are tailored to client needs, accommodating the scale of adoption or volume of product.In November 2021, Mythic Therapeutics, Inc. raised USD 103.10 mn in Series B funding, co-led by new investors Venrock and Viking Global Investors, with participation from several other investors. The funding will be utilized to advance their lead program through first-in-human clinical studies in lung cancer and to support pipeline development. The company aims to expand into new markets globally, although specific regions for this expansion have not been detailed.

## Funding rounds

- Series B, Nov 19, 2021, $103M — Venrock, First Round Capital, Highside Capital Management, Viking Global Investors, Capital Partners, Foresite Capital, Perceptive Advisors, Refactor Capital, LifeForce Capital, OMX Ventures
- Series A, Jul 31, 2020, $19M — BoxGroup

## Investors

- BoxGroup (https://capitalatlas.ai/funds/boxgroup) — Series A
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Series B
- Highside Capital Management — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Capital Partners — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Series B
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series B
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Series B